Matthew Korenberg's most recent trade in Palvella Therapeutics Inc. was a trade of 1,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Palvella Therapeutics Inc | Matthew E. Korenberg | CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2026 | 1,000 | 166,100 | - | - | Stock Option (Right to Buy) | |
| Palvella Therapeutics Inc | Matthew E. Korenberg | CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.60 per share. | 12 Jun 2026 | 1,000 | 1,000 | - | 13.6 | 13,600 | Common Stock |
| Lifecore Biomedical Inc | Matthew E. Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 25,907 | 69,967 (0%) | 0% | - | Common Stock | |
| Palvella Therapeutics Inc | Matthew E. Korenberg | CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 44,123 | 44,123 | - | - | Stock Option (Right to Buy) | |
| Lifecore Biomedical Inc | Matthew E. Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 19,506 | 44,060 (0%) | 0% | - | Common Stock | |
| Palvella Therapeutics Inc | Matthew Korenberg E. | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 123,559 | 123,559 | - | - | Non-Qualified Stock Option (right to buy) | |
| Palvella Therapeutics Inc | Matthew Korenberg E. | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 5,373 | 5,373 | - | - | Incentive Stock Option (right to buy) | |
| Palvella Therapeutics Inc | Matthew Korenberg | CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 167,100 | 167,100 | - | - | Stock Option (right to buy) | |
| Lifecore Biomedical Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 24,554 | 24,554 (0%) | 0% | - | Common Stock | |
| Ligand Pharma Inc (Class B) | Korenberg Matthew | PRESIDENT & CHIEF OPERATING | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.61 per share. | 05 Dec 2023 | 1,984 | 97,140 (0%) | 0% | 59.6 | 118,266 | Common Stock |
| Ligand Pharma Inc (Class B) | Matthew Korenberg | PRESIDENT & CHIEF OPERATING | Other type of transaction at price $ 56.78 per share. | 30 Jun 2023 | 376 | 99,124 (0%) | 0% | 56.8 | 21,349 | Common Stock |
| Ligand Pharma Inc (Class B) | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 24,628 | 24,628 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Matthew Korenberg | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,069 | 98,748 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Matthew Korenberg | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.98 per share. | 15 Feb 2023 | 2,890 | 89,679 (0%) | 0% | 73.0 | 210,912 | Common Stock |
| AIxCrypto Holdings Inc | Matthew Korenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) |